Merck Animal Health Announces Co-Promotion

Merck Animal Health Canada gets 2014 off to a running start with the announcement of key appointments in its equine division, and the forging of a strategic alliance that has resulted in the co-promotion of two partner products that complement the company’s extensive line of equine vaccines and pharmaceuticals.

NEW APPOINTMENTS

“In keeping with our long-standing commitment to supporting those who share our passion for equine health and well-being, we are extremely pleased to announce the appointment of Patrick Meyers, DVM, as Equine Technical Services Consultant and Key Account Manager,” says Kevin Ryan, Business Unit Director at Merck Animal Health. “Respected equine practitioner, board-certified theriogenologist, ORC official veterinarian, lecturer, teacher, author and industry consultant, Dr. Meyers brings to his new position a wealth of knowledge and experience that will undoubtedly be of great value to the equine community.”

“Our entire equine team, led by newly-appointed Senior Product Manager, Simon Grudzien, is more focused than ever on making sure equine practitioners and horse owners have access to the safe, effective and reliable products and services they need, and have come to expect from Merck Animal Health,” adds Ryan.

EXPANDED PRODUCT OFFERINGS

In an effort to leverage available resources and deliver the leading-edge tools the equine community needs, Merck Animal Health has forged a strategic alliance with Modern Veterinary Therapeutics, a pharmaceutical company dedicated to the research and development of innovative veterinary pharmaceuticals, biologics and diagnostics.

As a result of this co-marketing agreement, Merck Animal Health now delivers extra value to equine practitioners through the co-promotion of two modern veterinary therapeutics products.

• RESPIPULMINTM (clenbuterol hydrochloride syrup) is a bronchodilator syrup for oral use in horses only. It is recommended as an aid for the treatment of respiratory disease in horses, where it is considered that airway obstruction is due to bronchospasms. Clenbuterol, its active ingredient, has been shown to have intense bronchodilating properties with minimum effect on the cardiovascular system.

• CEPESEDANTM (detomidine hydrochloride injection) is a synthetic alpha-2 adrenoceptor agonist that produces sedation, and superficial and visceral analgesia. The chemical restraint and pain relief it provides help facilitate the handling of fractious animals, and aid in the conduct of uncomfortable diagnostic and/or therapeutic procedures.

“RESPIPULMINTM and CEPESEDANTM are ideal complements to our equine portfolio, providing clients with an even wider selection of practical tools that meet their needs – not to mention our rigorous quality standards… and theirs,” says Simon Grudzien, Senior Product Manager responsible for Merck Animal Health equine products.

INTRODUCTORY OFFER

According to Grudzien, “partnership has its privileges” – a point that is driven home by a special introductory offer on RESPIPULMINTM and CEPESEDANTM, that is being offered to veterinarians who purchase Merck Animal Health equine products between now and April 30, 2014.

Grudzien recommends that interested veterinarians register for the program without delay, adding: “Since purchases are tabulated monthly, the sooner clients sign up, the more time they’ll have to reap rewards!”

Veterinarians who would like to find out more about this promotion, and/or about RESPIPULMINTM, CEPESEDANTM and Merck Animal Health equine products, are invited to contact their local representative.